Praxis Precision Medicines (PRAX) News Today $45.85 +1.34 (+3.01%) Closing price 04:00 PM EasternExtended Trading$45.74 -0.11 (-0.23%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Former head trader of Denver-based investing company pleads guilty to insider tradingJune 9 at 5:01 AM | finance.yahoo.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Up 7.6% - Here's WhyPraxis Precision Medicines (NASDAQ:PRAX) Trading 7.6% Higher - Should You Buy?June 5, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | globenewswire.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Wellington Management Group LLPWellington Management Group LLP decreased its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 70.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 63,934 shares of theJune 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Holdings Reduced by Squarepoint Ops LLCSquarepoint Ops LLC decreased its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 46.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,782 shares of the company's stock after selling 6,June 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by AnalystsJune 3, 2025 | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and nine have issued a buyJune 3, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Coverage Initiated by Analysts at OppenheimerOppenheimer initiated coverage on Praxis Precision Medicines in a research note on Monday. They issued an "outperform" rating and a $97.00 price objective on the stock.June 2, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 5.6% - Time to Sell?June 1, 2025 | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial MarketsBNP Paribas Financial Markets cut its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 77.5% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,142 shares of the company's stock after selling 7,383 sJune 1, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 5.6% - Should You Sell?Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 5.6% - What's Next?May 31, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading 4.3% Higher - Should You Buy?Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 4.3% - Should You Buy?May 30, 2025 | marketbeat.comPolar Asset Management Partners Inc. Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Polar Asset Management Partners Inc. bought a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 98,617 shares of the company's stock, valued at apMay 28, 2025 | marketbeat.com9,948 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Purchased by Woodline Partners LPWoodline Partners LP bought a new position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 9,948 shares of the company's stock, valued atMay 28, 2025 | marketbeat.comVoloridge Investment Management LLC Buys 40,875 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Voloridge Investment Management LLC increased its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 54.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 116,062 shares of the company's stock after acquMay 27, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Millennium Management LLCMillennium Management LLC raised its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 3,519.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 150,892 shares of the company's stockMay 26, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Position Boosted by VR Adviser LLCVR Adviser LLC lifted its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 40.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 989,985 shares of the company's stock after buying an additional 283,854 shares duMay 22, 2025 | marketbeat.comVelan Capital Investment Management LP Sells 50,666 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Velan Capital Investment Management LP cut its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 14.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 300,000 shares of the company's stock after selling 50,666 shares during the periMay 21, 2025 | marketbeat.comSoleus Capital Management L.P. Sells 15,858 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Soleus Capital Management L.P. cut its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 6.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,540 shares of the company's stockMay 21, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Northern Trust Corp lifted its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 167,590 shares of the company's stock after buying an additional 15,323 sMay 19, 2025 | marketbeat.com98,617 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Acquired by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. acquired a new position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 98,617 shares of the company's stock, valued at approximatelyMay 18, 2025 | marketbeat.comEnsign Peak Advisors Inc Buys New Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Ensign Peak Advisors Inc bought a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 27,650 shares of the company's stock, valued at approximatelMay 18, 2025 | marketbeat.comNicholas Investment Partners LP Takes Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Nicholas Investment Partners LP acquired a new stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 8,481 shares of the company's sMay 17, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Janus Henderson Group PLCJanus Henderson Group PLC boosted its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 77.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 929,523 shares of the company's stoMay 16, 2025 | marketbeat.com11,634 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Acquired by J. Goldman & Co LPJ. Goldman & Co LP bought a new stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,634 shares of the company's stock, vMay 14, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and nine have assignedMay 11, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Now Covered by Chardan CapitalChardan Capital began coverage on Praxis Precision Medicines in a report on Wednesday. They set a "buy" rating and a $80.00 price target for the company.May 9, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of PRAX Q2 EarningsPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Investment analysts at HC Wainwright reduced their Q2 2025 EPS estimates for Praxis Precision Medicines in a research report issued to clients and investors on Monday, May 5th. HC Wainwright analyst D. Tsao now forecasts that the compMay 9, 2025 | marketbeat.comWedbush Issues Positive Forecast for PRAX EarningsPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Wedbush raised their Q2 2025 earnings estimates for Praxis Precision Medicines in a report released on Monday, May 5th. Wedbush analyst L. Chico now expects that the company will earn ($2.94) per share for the quarter, up from their pMay 9, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for PRAX FY2029 Earnings?Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities research analysts at HC Wainwright dropped their FY2029 EPS estimates for shares of Praxis Precision Medicines in a report issued on Monday, May 5th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnMay 8, 2025 | marketbeat.comWhat is Wedbush's Estimate for PRAX Q4 Earnings?Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities research analysts at Wedbush issued their Q4 2026 earnings per share (EPS) estimates for shares of Praxis Precision Medicines in a research note issued to investors on Monday, May 5th. Wedbush analyst L. Chico anticipates thaMay 8, 2025 | marketbeat.comPraxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock UpsideMay 7, 2025 | benzinga.comChardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy RecommendationMay 7, 2025 | msn.comPraxis Precision Medicines (NASDAQ:PRAX) Given New $28.00 Price Target at WedbushWedbush lifted their price objective on shares of Praxis Precision Medicines from $26.00 to $28.00 and gave the stock an "underperform" rating in a report on Monday.May 7, 2025 | marketbeat.comPraxis Precision Medicines (PRAX) Expected to Announce Quarterly Earnings on MondayPraxis Precision Medicines (NASDAQ:PRAX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-praxis-precision-medicines-inc-stock/)May 7, 2025 | marketbeat.comPraxis Precision Medicines' (PRAX) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $80.00 target price on shares of Praxis Precision Medicines in a research note on Monday.May 7, 2025 | marketbeat.comAlyeska Investment Group L.P. Takes Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Alyeska Investment Group L.P. acquired a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 226,788 shares of the company's stock, valued at approximatelyMay 7, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Holdings Raised by Baker BROS. Advisors LPBaker BROS. Advisors LP lifted its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 331,533 shares of the company's stock after purchasing an additional 8,428 shaMay 6, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Raises Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Schonfeld Strategic Advisors LLC raised its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 51.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4May 6, 2025 | marketbeat.comPraxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor EventMay 5, 2025 | finance.yahoo.comPraxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)May 4, 2025 | finance.yahoo.comPraxis Precision Medicines (NASDAQ:PRAX) Announces Earnings Results, Misses Estimates By $0.09 EPSPraxis Precision Medicines (NASDAQ:PRAX - Get Free Report) posted its earnings results on Friday. The company reported ($3.29) earnings per share for the quarter, missing the consensus estimate of ($3.20) by ($0.09). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%.May 4, 2025 | marketbeat.comAlly Bridge Group NY LLC Reduces Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Ally Bridge Group NY LLC lessened its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 38.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 44,982 shares of the company's stock after selling 28,203May 4, 2025 | marketbeat.com5AM Venture Management LLC Lowers Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)5AM Venture Management LLC decreased its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 50.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 170,000May 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Acuta Capital Partners LLCAcuta Capital Partners LLC lifted its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 17.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 67,500 shares of the company's stock after purchasing an additional 10,000May 4, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $105.00 target price on shares of Praxis Precision Medicines in a research note on Thursday.May 3, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 2, 2025 | globenewswire.comPrice T Rowe Associates Inc. MD Has $93.01 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Price T Rowe Associates Inc. MD increased its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 7.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,208,522 shares of the companyApril 30, 2025 | marketbeat.comTri Locum Partners LP Takes $2.87 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Tri Locum Partners LP purchased a new position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 37,269 shares of the company's stock, valued at appApril 29, 2025 | marketbeat.com Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAX Media Mentions By Week PRAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRAX News Sentiment▼0.320.68▲Average Medical News Sentiment PRAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRAX Articles This Week▼65▲PRAX Articles Average Week Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Protagonist Therapeutics News Today Catalyst Pharmaceuticals News Today Crinetics Pharmaceuticals News Today Metsera News Today Viking Therapeutics News Today MorphoSys News Today Scholar Rock News Today Kymera Therapeutics News Today MoonLake Immunotherapeutics News Today Immunovant News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRAX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
